BioAge Labs Files for IPO

BioAge Labs (BIOA) has announced its filing for a proposed IPO. The company is a clinical-stage biopharmaceutical firm focused on developing therapies for metabolic diseases, particularly obesity, by targeting the biology of human aging.

Company Overview

BioAge Labs claims, “We are a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging.” Their technology platform utilizes unique human datasets to identify promising targets based on insights into molecular changes that drive aging.

Lead Product Candidate

The lead product candidate, azelaprag, is an orally available small molecule. It has shown good tolerability in 265 individuals through eight Phase 1 clinical trials. In preclinical obesity models, azelaprag was able to more than double the weight loss induced by a glucagon-like-peptide-1 receptor (GLP-1R) agonist while also improving muscle function and restoring healthy body composition.

Clinical Trials

Preliminary results from a Phase 1b clinical trial among older adults on bed rest indicate decreased muscle atrophy and better muscle quality and metabolism after azelaprag treatment over a 10-day period. Future Phase 2 trials will explore azelaprag’s effectiveness in combination with a GLP-1R agonist for enhancing weight loss, with one trial combining it with tirzepatide (Zepbound®) anticipated to yield topline results by Q3 2025, and another with semaglutide (Wegovy®) expected to begin in H1 2025.

Additional Developments

BioAge Labs is also working on orally available small molecule brain-penetrant NLRP3 inhibitors targeting neuroinflammatory diseases, with plans to submit an Investigational New Drug (IND) application in H2 2025 and start a Phase 1 clinical trial in H1 2026.

Underwriters

Goldman Sachs & Co (NYSE:GS), Morgan Stanley, Jefferies, and Citigroup will serve as underwriters for the IPO.